 |
市场调查报告书
商品编码
1616250
泌尿生殖药物市场机会、成长动力、产业趋势分析与预测 2024 - 2032Genitourinary Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032 |
||||||
2023 年，全球泌尿生殖药物市场规模达到 287 亿美元，2024 年至 2032 年复合年增长率将达到 2.3%。肿瘤学的最新进展，特别是前列腺癌治疗的进展，正在对市场产生重大影响。例如，2024年3月，百时美施贵宝宣布FDA批准Opdivo（nivolumab）合併顺铂和吉西他滨用于第一线治疗不可切除或转移性尿路上皮癌（UC）成年患者。此次批准旨在增强公司的竞争地位和市场影响力。
市场依药物类型分为荷尔蒙疗法、抗感染药和其他药物类型。荷尔蒙疗法是晚期前列腺癌的主要治疗方法，通常利用雄性激素剥夺疗法 (ADT) 来降低睪固酮水平。全球前列腺癌发生率的上升增加了对荷尔蒙疗法的需求。长效型储库製剂无需频繁给药，可提高病患依从性和治疗效果，进一步推动市场成长。
全球人口老化也增加了对荷尔蒙疗法的需求，以治疗荷尔蒙相关的泌尿生殖系统疾病，如前列腺癌和良性前列腺增生 (BPH)。在应用方面，到 2023 年，泌尿道感染 (UTI) 领域将占据超过 31% 的市场份额。早期诊断和治疗至关重要，这会增加对泌尿道感染药物的需求并推动市场成长。许多患者会经历復发性泌尿道感染，需要重复治疗。
| 市场范围 | |
|---|---|
| 开始年份 | 2023年 |
| 预测年份 | 2024-2032 |
| 起始值 | 287 亿美元 |
| 预测值 | 349 亿美元 |
| 复合年增长率 | 2.3% |
这种高復发率刺激了对长期预防性治疗的需求，从而促进了市场成长。北美泌尿生殖药物市场预计将以2.1% 的复合年增长率成长，到2032 年将达到154 亿美元。的医疗基础设施和持续的研究和发展。肥胖和糖尿病等与生活方式相关的疾病发病率不断增加，与泌尿生殖系统疾病的增加有关，进一步推动了市场的成长。美国食品药物管理局 (FDA) 的监管批准在塑造市场格局方面发挥着至关重要的作用，新药的批准扩大了治疗选择。
目录
第 1 章：方法与范围
第 2 章：执行摘要
第 3 章：产业洞察
- 产业生态系统分析
- 产业影响力
- 成长动力
- 泌尿生殖系统疾病盛行率增加
- 药物开发技术的进步
- 药物传输技术的进步
- 产业陷阱与挑战
- 来自非药物疗法的竞争
- 与泌尿生殖药物相关的显着副作用
- 成长动力
- 成长潜力分析
- 监管环境
- 未来市场趋势
- 管道分析
- 波特的分析
- PESTEL分析
第 4 章：竞争格局
- 介绍
- 公司市占率分析
- 公司矩阵分析
- 主要市场参与者的竞争分析
- 竞争定位矩阵
- 战略仪錶板
第 5 章：市场估计与预测：按药物类型，2021 - 2032
- 主要趋势
- 荷尔蒙疗法
- 雄激素
- 雌激素
- 其他荷尔蒙疗法
- 抗感染
- 抗生素
- 抗霉菌药
- 抗病毒药
- 其他药物类型
第 6 章：市场估计与预测：按应用分类，2021 - 2032
- 主要趋势
- 泌尿道感染（UTI）
- 良性摄护腺增生（BPH）
- 摄护腺癌
- 膀胱过动症
- 膀胱癌
- 其他应用
第 7 章：市场估计与预测：按给药途径，2021 - 2032 年
- 主要趋势
- 口服
- 注射用
- 专题
第 8 章：市场估计与预测：按配销通路，2021 - 2032 年
- 主要趋势
- 医院药房
- 药局和零售药局
- 网路药局
第 9 章：市场估计与预测：按地区，2021 - 2032
- 主要趋势
- 北美洲
- 我们
- 加拿大
- 欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
- 亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
- 中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区
第 10 章：公司简介
- Abbott Laboratories
- Allergan, Inc.
- AstraZeneca Plc
- Bayer AG
- Bristol-Myers Squibb Co.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Ionis Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd
The Global Genitourinary Drugs market size reached USD 28.7 billion in 2023 and will record 2.3% CAGR between 2024 and 2032. Innovative hormonal therapies are driving industry growth by offering more effective and safer options. Recent advancements in oncology, particularly in prostate cancer therapeutics, are significantly impacting the market. For instance, in March 2024, Bristol Myers Squibb announced FDA approval for Opdivo (nivolumab) combined with cisplatin and gemcitabine for first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC). This approval is set to enhance the company's competitive position and market reach.
The market is segmented by drug type into hormonal therapy, anti-infectives, and other drug types. Hormonal therapy serves as a primary treatment for advanced prostate cancer, often utilizing androgen deprivation therapy (ADT) to lower testosterone levels. The global rise in prostate cancer incidence is increasing the demand for hormonal therapies. Long-acting depot formulations, which require less frequent dosing, improve patient compliance and treatment outcomes, further driving market growth.
The aging global population is also raising the demand for hormonal therapies to manage hormone-related genitourinary disorders such as prostate cancer and benign prostatic hyperplasia (BPH). In terms of applications, the urinary tract infections (UTIs) segment held over 31% market share in 2023. Public health campaigns have increased awareness of UTI symptoms and complications, leading to higher diagnosis rates. Early diagnosis and treatment are crucial, boosting the demand for UTI medications and driving market growth. Many patients experience recurrent UTIs, necessitating repeated treatments.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $28.7 Billion |
| Forecast Value | $34.9 Billion |
| CAGR | 2.3% |
This high recurrence rate fuels the demand for long-term and prophylactic therapies, contributing to market growth. North America genitourinary drugs market is projected to grow at a CAGR of 2.1%, reaching USD 15.4 billion by 2032. The U.S. market, a significant segment of the pharmaceutical industry, is driven by a high prevalence of genitourinary disorders, advanced healthcare infrastructure, and ongoing research and development. The increasing incidence of lifestyle-related disorders such as obesity and diabetes is linked to a rise in genitourinary conditions, further fueling market growth. Regulatory approvals by the U.S. Food and Drug Administration (FDA) play a crucial role in shaping the market landscape, with new drug approvals expanding treatment options.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of genitourinary disorders
- 3.2.1.2 Rise in advancement in drug development technology
- 3.2.1.3 Technological advancement in drug delivery
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Competition from non-pharmaceutical therapies
- 3.2.2.2 Significant side effects associated with genitourinary drugs
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Future market trends
- 3.6 Pipeline analysis
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Hormonal therapy
- 5.2.1 Androgen
- 5.2.2 Estrogen
- 5.2.3 Other hormonal therapy
- 5.3 Anti-infective
- 5.3.1 Antibiotics
- 5.3.2 Antifungals
- 5.3.3 Antivirals
- 5.4 Other drug types
Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Urinary tract infections (UTIs)
- 6.3 Benign prostatic hyperplasia (BPH)
- 6.4 Prostate cancer
- 6.5 Overactive bladder
- 6.6 Bladder cancer
- 6.7 Other applications
Chapter 7 Market Estimates and Forecast, By Route of administration, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Oral
- 7.3 Parenteral
- 7.4 Topical
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospital pharmacies
- 8.3 Drug store & retail pharmacies
- 8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Abbott Laboratories
- 10.2 Allergan, Inc.
- 10.3 AstraZeneca Plc
- 10.4 Bayer AG
- 10.5 Bristol-Myers Squibb Co.
- 10.6 Eli Lilly and Company
- 10.7 F. Hoffmann-La Roche Ltd.
- 10.8 GlaxoSmithKline Plc
- 10.9 Ionis Pharmaceuticals, Inc.
- 10.10 Merck & Co., Inc.
- 10.11 Novartis AG
- 10.12 Pfizer, Inc.
- 10.13 Teva Pharmaceutical Industries Ltd
